NASDAQ:BIIB - Biogen Price Target & Analyst Ratings Sign in or create an account to add this stock to your watchlist. Get Started $345.41 +4.17 (+1.22 %) (As of 09/21/2018 04:00 PM ET)Previous Close$341.24Today's Range$338.52 - $345.4152-Week Range$249.17 - $388.67Volume3.87 million shsAverage Volume1.67 million shsMarket Capitalization$68.27 billionP/E Ratio15.68Dividend YieldN/ABeta0.9 Company ProfileDiscussionAnalyst RatingsChartEarnings HistoryFinancialsInsider TradesHeadlinesOptions ChainSEC FilingsSocial Media Share on FacebookShare on TwitterShare on LinkedInShare on RedditShare on StocktwitsPrint this articleShare by Email Analyst Ratings Biogen (NASDAQ:BIIB) Price Target and Consensus Rating (How are Consensus Ratings Calculated?) MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.29 Wall Street analysts have issued ratings and price targets for Biogen in the last 12 months. Their average twelve-month price target is $375.5241, suggesting that the stock has a possible upside of 8.72%. The high price target for BIIB is $483.00 and the low price target for BIIB is $262.15. There are currently 9 hold ratings and 20 buy ratings for the stock, resulting in a consensus rating of "Buy."Today30 Days Ago90 Days Ago180 Days AgoConsensus Rating: BuyBuyBuyBuyConsensus Rating Score: 2.692.692.722.72Ratings Breakdown: 0 Sell Rating(s)9 Hold Rating(s)20 Buy Rating(s)0 Strong Buy Rating(s)0 Sell Rating(s)9 Hold Rating(s)20 Buy Rating(s)0 Strong Buy Rating(s)0 Sell Rating(s)8 Hold Rating(s)21 Buy Rating(s)0 Strong Buy Rating(s)0 Sell Rating(s)8 Hold Rating(s)21 Buy Rating(s)0 Strong Buy Rating(s)Consensus Price Target: $375.5241$375.5241$353.4130$370.9259Price Target Upside: 8.72% upside10.07% upside18.34% upside32.52% upsideBiogen (NASDAQ:BIIB) Consensus Price Target History Biogen (NASDAQ:BIIB) Analyst Ratings History Show: Only the Most Recent Rating From Each Brokerage All Ratings For This Stock DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails9/16/2018OppenheimerSet Price TargetBuy$400.00Medium8/7/2018Stifel NicolausInitiated CoverageBuy$394.00High7/31/2018MizuhoReiterated RatingBuy$427.00Low7/26/2018CitigroupBoost Price TargetBuy ➝ Positive$483.00Medium7/26/2018UBS GroupBoost Price TargetBuy ➝ Buy$354.00 ➝ $395.00Medium7/25/2018Cantor FitzgeraldSet Price TargetHold$293.00Low7/25/2018BarclaysBoost Price TargetEqual Weight ➝ Equal Weight$295.00 ➝ $320.00High7/25/2018Robert W. BairdBoost Price TargetNeutral ➝ Neutral$323.00 ➝ $348.00High7/25/2018SunTrust BanksBoost Price TargetBuy$321.00 ➝ $392.00High7/25/2018Morgan StanleyBoost Price TargetOverweight ➝ Overweight$366.00 ➝ $392.00High7/24/2018GuggenheimReiterated RatingBuy$410.00High7/24/2018CowenReiterated RatingBuy$408.00High7/24/2018JPMorgan Chase & Co.Boost Price TargetOverweight ➝ Hold$400.00 ➝ $445.00High7/23/2018Canaccord GenuityBoost Price TargetBuy ➝ Buy$335.00 ➝ $396.00Low7/11/2018Piper Jaffray CompaniesBoost Price TargetOverweight$365.00Low7/10/2018Royal Bank of CanadaBoost Price TargetMarket Perform$349.00Medium7/9/2018Jefferies Financial GroupBoost Price TargetPositive ➝ Hold$400.00Medium7/9/2018HC WainwrightReiterated RatingBuyMedium7/6/2018NomuraReiterated RatingBuy$420.00High4/25/2018Leerink SwannSet Price TargetMarket Perform ➝ Hold$365.00 ➝ $325.00High4/25/2018Goldman Sachs GroupDowngradeConviction-Buy ➝ Buy$388.00 ➝ $262.15High4/24/2018Credit Suisse GroupSet Price TargetBuy$384.00High4/10/2018Sanford C. BernsteinSet Price TargetBuy$318.00Medium3/2/2018BMO Capital MarketsLower Price TargetOutperform ➝ Outperform$403.00 ➝ $393.00Low2/16/2018ArgusDowngradeBuy ➝ HoldMedium2/15/2018William BlairReiterated RatingBuyLow1/26/2018Deutsche BankReiterated RatingBuy$373.00Low10/18/2017Bank of AmericaBoost Price TargetBuy$358.00 ➝ $365.00N/A9/21/2017Raymond JamesDowngradeStrong-Buy ➝ Market Perform$244.28 ➝ $319.00Low3/1/2017InstinetInitiated CoverageBuy ➝ Buy$223.03 ➝ $345.00N/A(Data available from 9/21/2016 forward) This page was last updated on 9/21/2018 by MarketBeat.com StaffFeatured Article: What is Compound Annual Growth Rate (CAGR)?